Anti-C3 抗体 (ab97462)
Key features and details
- Rabbit polyclonal to C3
- Suitable for: IHC-P, IP, WB, ICC/IF
- Reacts with: Mouse, Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-C3 antibody
C3/C3b 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to C3 -
由来種
Rabbit -
アプリケーション
適用あり: IHC-P, IP, WB, ICC/IFmore details -
種交差性
交差種: Mouse, Human -
免疫原
Recombinant fragment, corresponding to a region within amino acids 1498 - 1625 of Human C3.
-
ポジティブ・コントロール
- WB: HepG2 and Huh7 whole cell lysate. ICC/IF: HeLa cells. IHC: H1299 xenograft tissue; mouse brain tissue. IP: HepG2 whole cell extract.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.00
Preservative: 0.025% Proclin 300
Constituents: 78% PBS, 1% BSA, 20% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab97462の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-P | (1) |
1/100 - 1/1000.
|
IP |
1/100 - 1/500.
|
|
WB |
1/500 - 1/3000. Predicted molecular weight: 187 kDa.
|
|
ICC/IF |
1/100 - 1/1000.
|
特記事項 |
---|
IHC-P
1/100 - 1/1000. |
IP
1/100 - 1/500. |
WB
1/500 - 1/3000. Predicted molecular weight: 187 kDa. |
ICC/IF
1/100 - 1/1000. |
ターゲット情報
-
機能
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. -
組織特異性
Plasma. -
関連疾患
Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. -
配列類似性
Contains 1 anaphylatoxin-like domain.
Contains 1 NTR domain. -
翻訳後修飾
C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
Phosphorylation sites are present in the extracelllular medium. -
細胞内局在
Secreted. - Information by UniProt
-
参照データベース
- Entrez Gene: 718 Human
- Entrez Gene: 12266 Mouse
- Omim: 120700 Human
- SwissProt: P01024 Human
- SwissProt: P01027 Mouse
- Unigene: 529053 Human
- Unigene: 19131 Mouse
-
別名
- Acylation stimulating protein cleavage product antibody
- AHUS5 antibody
- ARMD9 antibody
see all
画像
-
All lanes : Anti-C3 antibody (ab97462) at 1/1000 dilution
Lane 1 : Huh7 whole cell lysate
Lane 2 : HepG2 (human liver hepatocellular carcinoma cell line) whole cell lysate
Lysates/proteins at 30 µg per lane.
Secondary
All lanes : HRP-conjugated anti-rabbit IgG
Predicted band size: 187 kDa5% SDS-PAGE.
-
HeLa (human epithelial cell line from cervix adenocarcinoma) cells labeling C3 with ab97462 at 1/200 dilution (green) in ICC/IF. Cells were fixed in 4% paraformaldehyde at room temperature for 15 minutes.
Nuclei were stained using Hoechst 33342 (blue).
-
Paraffin-embedded mouse brain tissue stained for C3 using ab97462 at 1/500 dilution in immunohistochemical analysis.
-
C3 was immunoprecipitated from HepG2 (human liver hepatocellular carcinoma cell line) whole cell extracts using 5 μg of ab97462. Western blot was performed from the immunoprecipitate using ab97462.
Lane 1: HepG2 whole cell extract.
Lane 2: Control IgG instead of ab97462 in HepG2 whole cell extract.
Lane 3: ab97462 IP in HepG2 whole cell extract.
-
Anti-C3 antibody (ab97462) at 1/1500 dilution + HepG2 whole cell lysate at 30 µg
Predicted band size: 187 kDa
7.5% SDS-PAGE. -
ab97462 at 1/100 dilution staining C3 in HeLa cells by Immunofluorescence, Paraformaldehyde fixed. Lower image shows cells co-stained with Hoechst 33342.
-
ab97462 at 1/100 dilution staining C3 in H1299 xenograft by Immunohistochemistry, Paraffin-embedded tissue.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (16)
ab97462 は 16 報の論文で使用されています。
- Jiao Y et al. Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: Evidence from transcriptomic data and renal histopathology. J Diabetes Investig 13:839-849 (2022). PubMed: 34932275
- Vicente-Acosta A et al. The smoothened agonist SAG reduces mitochondrial dysfunction and neurotoxicity of frataxin-deficient astrocytes. J Neuroinflammation 19:93 (2022). PubMed: 35413853
- Jiang S et al. Activation of Complement Pathways in Kidney Tissue May Mediate Tubulointerstitial Injury in Diabetic Nephropathy. Front Med (Lausanne) 9:845679 (2022). PubMed: 35479942
- Zha Z et al. Bu Shen Yi Sui Capsule Promotes Myelin Repair by Modulating the Transformation of A1/A2 Reactive Astrocytes In Vivo and In Vitro. Oxid Med Cell Longev 2022:3800004 (2022). PubMed: 36092158
- Yang G & Shi J miRNA-130a-3p targets sphingosine-1-phosphate receptor 1 to activate the microglial and astrocytes and to promote neural injury under the high glucose condition. Open Med (Wars) 17:2117-2129 (2022). PubMed: 36582210